Wenxin (Vincent) Xu, MD

KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

A phase 0 trial is seeking to assess the feasibility of aiding anticancer cells with cytokines to restore their function.

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

Panelists discuss the dosing schedule and patient education related to tivozanib, along with indications for potential treatment switch based on toxicity management and patient well-being.

Perspectives on the adverse events and management of tivozanib, covering common and serious toxicities with an emphasis on a multidisciplinary approach to optimize patient care and treatment benefits.

Experts from the Dana-Farber Cancer Institute delve into the TIVO-3 trial, discussing the design, outcomes, and nuances of tivozanib as a treatment option for refractory kidney cancer.

Expert insight into monitoring patients with advanced kidney cancer, covering the frequency of clinic visits, blood work, and CT scans, as well as signs and symptoms that might indicate disease progression.

Reviewing the case of a case of a 73-year-old man with metastatic clear cell kidney cancer, experts discuss second-line treatment options informed by prior treatment response, patient goals, and adverse event profiles.

Insight into the importance of patient-centered care, highlighting the role of a multidisciplinary team in managing advanced renal cell carcinoma and addressing questions regarding alternative medications.

Key opinion leaders reflect on treatment approaches for renal cell carcinoma in light of factors like risk classification, symptom severity, and patient preferences, with considerations ranging from active surveillance to systemic combination therapies.

Expert discussion focused on approved therapies for first-line kidney cancer treatment including combination therapies, immunotherapy, and tyrosine kinase inhibitors (TKIs) in various clinical scenarios.

Join Wenxin (Vincent) Xu, MD, and his team at Dana-Farber Cancer Institute as they explore strategies for diagnosing and stratifying renal cell carcinoma, reviewing a clinical scenarios and best practices in workup.